Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

PharmacoEconomics

Showing results (31-40 of 3,929) with videos related to

Pageof 393
Sort By:
Pharmacoeconomics|November 8, 2017
Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix<sup>®</sup>) to Guide Treatment of Patients with Depression and/or AnxietyMehdi Najafzadeh, Jorge A Garces, Alejandra Maciel
Pharmacoeconomics|August 10, 2016
Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?T Joseph Mattingly, C Daniel Mullins, Eberechukwu Onukwugha
Pharmacoeconomics|June 1, 2015
A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)Feng Xie, A Simon Pickard, Paul F M Krabbe, et al.
Pharmacoeconomics|February 5, 2025
EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19?Wenjing Zhou, Bo Ding, Jan Busschbach, et al.
Pharmacoeconomics|February 7, 2025
Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in OncologyAstrid Kramer, Lucas F van Schaik, Daan van den Broek, et al.
Pharmacoeconomics|January 11, 2025
Projections of Public Spending on Pharmaceuticals: A Review of MethodsIrina Odnoletkova, Patrice X Chalon, Stephan Devriese, et al.
Pharmacoeconomics|January 17, 2025
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target PopulationsGeorgia Pick, Dirk Müller, Charalabos-Markos Dintsios
Pharmacoeconomics|December 6, 2024
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice ExperimentSakil Syeed, Chia Jie Tan, Amandeep Godara, et al.
Pharmacoeconomics|December 5, 2024
How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal SurveyBecky Pennington, Mónica Hernández Alava, Mark Strong
Pharmacoeconomics|December 4, 2024
Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast CancerTrang T H Nguyen, Shweta Mital
Pageof 393

Showing results (31-40 of 3,929) with videos related to

Sort By:
Pageof 393
Pharmacoeconomics|November 8, 2017
Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix<sup>®</sup>) to Guide Treatment of Patients with Depression and/or AnxietyMehdi Najafzadeh, Jorge A Garces, Alejandra Maciel
Pharmacoeconomics|August 10, 2016
Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?T Joseph Mattingly, C Daniel Mullins, Eberechukwu Onukwugha
Pharmacoeconomics|June 1, 2015
A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)Feng Xie, A Simon Pickard, Paul F M Krabbe, et al.
Pharmacoeconomics|February 5, 2025
EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19?Wenjing Zhou, Bo Ding, Jan Busschbach, et al.
Pharmacoeconomics|February 7, 2025
Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in OncologyAstrid Kramer, Lucas F van Schaik, Daan van den Broek, et al.
Pharmacoeconomics|January 11, 2025
Projections of Public Spending on Pharmaceuticals: A Review of MethodsIrina Odnoletkova, Patrice X Chalon, Stephan Devriese, et al.
Pharmacoeconomics|January 17, 2025
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target PopulationsGeorgia Pick, Dirk Müller, Charalabos-Markos Dintsios
Pharmacoeconomics|December 6, 2024
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice ExperimentSakil Syeed, Chia Jie Tan, Amandeep Godara, et al.
Pharmacoeconomics|December 5, 2024
How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal SurveyBecky Pennington, Mónica Hernández Alava, Mark Strong
Pharmacoeconomics|December 4, 2024
Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast CancerTrang T H Nguyen, Shweta Mital
Pageof 393